Cargando…
Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes
Autores principales: | Hu, Jing-Yi, Zou, Hai-Lan, Li, Yan-Hua, Nie, Dong-Ying, Chao, Chen, Liu, Jin-Han, Ding, Jin, Zhou, Zhi-Guang, Xiao, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478367/ https://www.ncbi.nlm.nih.gov/pubmed/34475326 http://dx.doi.org/10.1097/CM9.0000000000001574 |
Ejemplares similares
-
Atherogenic dyslipidemia
por: Manjunath, C. N., et al.
Publicado: (2013) -
Prevalence and Predictors of Atherogenic Serum Lipoprotein Dyslipidemia in Women with Obstructive Sleep Apnea
por: Xia, Yunyan, et al.
Publicado: (2017) -
Search for genetic factors predisposing to atherogenic dyslipidemia
por: Yip, Agustin G, et al.
Publicado: (2003) -
Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention
por: Musunuru, Kiran
Publicado: (2010) -
Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
por: Vekic, Jelena, et al.
Publicado: (2023)